argenx SE (EBR:ARGX)
552.00
+0.20 (0.04%)
Mar 28, 2025, 5:35 PM CET
argenx SE Revenue
In the year 2024, argenx SE had annual revenue of $2.25B USD with 77.22% growth. argenx SE had revenue of $757.39M in the quarter ending December 31, 2024, with 81.26% growth.
Revenue
$2.25B
Revenue Growth
+77.22%
P/S Ratio
15.22
Revenue / Employee
$1.96M
Employees
1,148
Market Cap
33.67B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UCB SA | 6.15B |
Financière de Tubize | 13.26K |
Fagron NV | 871.96M |
Ion Beam Applications | 465.75M |
Nyxoah | 4.52M |
Onward Medical | -188.00K |
Hyloris Pharmaceuticals | 10.04M |
Sequana Medical NV | 433.50K |
argenx SE News
- 3 days ago - Looking Into argenx's Recent Short Interest - Benzinga
- 5 days ago - Argenx: The Magic May Be Already Priced In - Seeking Alpha
- 9 days ago - P/E Ratio Insights for argenx - Benzinga
- 23 days ago - argenx SE (ARGX) Announces Promising Data for VYVGART at AAN Annual Meeting - GuruFocus
- 23 days ago - argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 4 weeks ago - argenx targets 12,000 CIDP patients with VYVGART expansion in 2025 - Seeking Alpha
- 4 weeks ago - argenx SE (ARGX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent - Seeking Alpha